EP0000151A1 - 1-Substituted aminoindolines, process for their production and pharmaceutical compositions containing them - Google Patents
1-Substituted aminoindolines, process for their production and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- EP0000151A1 EP0000151A1 EP78100166A EP78100166A EP0000151A1 EP 0000151 A1 EP0000151 A1 EP 0000151A1 EP 78100166 A EP78100166 A EP 78100166A EP 78100166 A EP78100166 A EP 78100166A EP 0000151 A1 EP0000151 A1 EP 0000151A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrogen
- compound
- formula
- carbon atoms
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to 1-aminoindoline derivatives.
- Alkyl, alkoxy and alkylthio preferably contain 1 or 2, especially 1 carbon atom.
- Halogen is preferably chlorine.
- R 1 , R 21 R 3 and R 5 are preferably hydrogen.
- R 4 is preferably hydrogen, alkyl or halogen, especially hydrogen.
- R 3 is preferably in the 3 position of the indoline nucleus.
- R 4 is preferably in the 4, 5 or 6, especially in the 4 or 5, preferably in the 4-position.
- n is preferably 2.
- a compound of formula I may be obtained by a process comprising cyclizing a compound of formula II, wherein R 1 to R 5 and n are as defined above and X is a leaving group.
- the process according to the invention may be effected in a manner analogous to known methods for cyclizing analogous amino derivatives.
- X is e.g. a group -NHR a , wherein R is alkyl of 1 to 4 carbon atoms, especially methyl, or R a is hydrogen.
- the reaction is preferably effected in an inert solvent such as methanol or ethanol, or, when the amine of formula IV (see below) is liquid at the reaction temperature, the reaction is conveniently effected in the absence of any additional solvent.
- the reaction is preferably effected in the presence of a mineral acid such as hydrochloric or hydroiodic acid.
- the reaction temperature may be from room temperature to about 150°C and is preferably at least 50°C, e.g. the boiling temperature of the reaction mixture.
- the compounds of formula I may be isolated and purified in accordance with known methods.
- the compounds of formula I may be present in free form, or in the form.of acid addition salts.
- Acid addition salt forms for example, the hydrochloride or hydrogen maleate, may be produced from the free form in known manner, and vice-versa.
- the compounds of formula I may also be present intauto- meric form, i.e. with the double bond adjacent to one of the other two nitrogen atoms of the guanidine moiety, insofar this nitrogen atom is not substituted by an alkyl group R 1 or R 2 . It is to be appreciated that such tautomeric forms also fall under the scope of formula I.
- the production of the starting materials may be effected in known manner.
- a compound of formula II may e.g. be produced by reacting a compound of formula III, wherein R 3 to R5 and X are as defined above and the group -S-Y is a leaving group, with a compound of formula IV, wherein R 1 , R 2 and n are as defined above.
- Y may e.g. be alkyl of 1 to 4 carbon atoms, preferably methyl.
- the reaction conditions may be chosen such as to be identical with the conditions for cyclization according to the invention.
- the compounds of formula III are then advantageously reacted with the compounds of formula IV to give directly the corresponding compounds of formula I, without intermediate isolation of the compounds of formula II.
- the starting material is obtained as follows.
- 1-Aminoindoline is reacted with benzoyl isothiocyanate in boiling tetrahydrofurane and, after saponification of the product over 15 minutes with diluted sodium hydroxide under reflux, l-(indolin-l-yl)thiourea (M.P. 225-227° - from methanol) is obtained.
- This product is converted into 1-(indolin-1-yl)-2-methyl- isothiourea hydroiodide by heating up for 1 hour with methyl iodide in methanol.
- the free base is obtained by addition of aqueous sodium hydroxide and is further reacted with a 2N methanolic solution of hydrochloric acid to give l-(indolin-l-yl)-2-methylisothiourea hydrochloride (M.P. 227-229° - from methanol/ether).
- the compounds of formula I exhibit pharmacological activity.
- the compounds possess vasoconstricting activity, as indicated by standard tests.
- this activity may be observed in vivo in rats treated in accordance with the principles of J.S. Gillespie and T.C. Muir, Br.J. Pharmac.Chemother. (1967) 30, 78-87): a pressor effect is elicited following i.v. administration of from about 0.02 to about 50 ⁇ g/kg, particularly of from about 0.02 to about 0.5 pg/kg of the compounds.
- the compounds are therefore indicated for use as vasoconstricting agents, e.g. for the prophylaxis and treatment of vascular headaches such as migraine, and of orthostatic disorders such as orthostatic hypotension and its symptoms, such as vertigo.
- an indicated daily dose is from about 0.0025 to about 1 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage from containing from about 0.0005 to about 0.5 mg, or in sustained release form.
- the activity of the compound of Example 1 is especially interesting.
- the compounds of formula I may be administered in free form or in pharmaceutically acceptable acid addition salt form. Such forms exhibit the same order of activity as the free form.
- the present invention also provides a pharmaceutical composition comprising a compound of formula I, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent. Such compositions may be in the form of, for example, a solution or a tablet.
Abstract
Description
- The present invention relates to 1-aminoindoline derivatives.
-
- one of R1 and R2 is hydrogen and the other is hydrogen or alkyl of 1 to 4 carbon atoms,
- R3 is hydrogen or alkyl of 1 to 4 carbon atoms, in the 2- or 3-position,
- R4 and R5 independently are hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to'4 carbon atoms, alkylthio of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35, and n is 2, 3 or 4.
- Alkyl, alkoxy and alkylthio preferably contain 1 or 2, especially 1 carbon atom. Halogen is preferably chlorine.
- R1, R21 R3 and R5 are preferably hydrogen. R4 is preferably hydrogen, alkyl or halogen, especially hydrogen.
- R3 is preferably in the 3 position of the indoline nucleus. R4 is preferably in the 4, 5 or 6, especially in the 4 or 5, preferably in the 4-position.
n is preferably 2. -
- The process according to the invention may be effected in a manner analogous to known methods for cyclizing analogous amino derivatives. X is e.g. a group -NHRa, wherein R is alkyl of 1 to 4 carbon atoms, especially methyl, or Ra is hydrogen. The reaction is preferably effected in an inert solvent such as methanol or ethanol, or, when the amine of formula IV (see below) is liquid at the reaction temperature, the reaction is conveniently effected in the absence of any additional solvent. The reaction is preferably effected in the presence of a mineral acid such as hydrochloric or hydroiodic acid. The reaction temperature may be from room temperature to about 150°C and is preferably at least 50°C, e.g. the boiling temperature of the reaction mixture.
- The compounds of formula I may be isolated and purified in accordance with known methods.
- The compounds of formula I may be present in free form, or in the form.of acid addition salts. Acid addition salt forms, for example, the hydrochloride or hydrogen maleate, may be produced from the free form in known manner, and vice-versa.
- The compounds of formula I may also be present intauto- meric form, i.e. with the double bond adjacent to one of the other two nitrogen atoms of the guanidine moiety, insofar this nitrogen atom is not substituted by an alkyl group R1 or R2. It is to be appreciated that such tautomeric forms also fall under the scope of formula I.
- The production of the starting materials may be effected in known manner.
-
- Y may e.g. be alkyl of 1 to 4 carbon atoms, preferably methyl. The reaction conditions may be chosen such as to be identical with the conditions for cyclization according to the invention. The compounds of formula III are then advantageously reacted with the compounds of formula IV to give directly the corresponding compounds of formula I, without intermediate isolation of the compounds of formula II.
- When in the compounds of formula III Y is alkyl of 1 to 4 carbon atoms and X is a group -NH-R , the reaction conditions for producing compounds of formula I directly from corresponding compounds of formula III.are analogous to known reaction conditions for the production of a l-(indolin-l-yl)-guanidine derivative from a l-(indolin-1-yl)-2-(lower)alkylisothiourea.
- Insofar as the production of the starting materials is not described, these are known or may be produced and purified in accordance with known processes, or in a manner analogous to the processes described above or analogous to known processes.
- In the following non-limitative Examples all temperatures are indicated in degrees Centigrade and are uncorrected.
- To 10 g 1-(indolin-1-yl)-2-methylisothiourea hydrochloride dissolved in 40 ml ethanol are added 8 mi ethylene diamine and the reaction mixture is boiled for 6 hours with stirring. The mixture is then evaporated to dryness and the residue is extracted from a 1 M solution of sodium hydroxide with methylene chloride. The organic phase is then dried over magnesium sulphate and evaporated. The title compound is obtained (M.P. of the hydrogen maleate 171-172° - from ethanol/ether).
- The starting material is obtained as follows.
- 1-Aminoindoline is reacted with benzoyl isothiocyanate in boiling tetrahydrofurane and, after saponification of the product over 15 minutes with diluted sodium hydroxide under reflux, l-(indolin-l-yl)thiourea (M.P. 225-227° - from methanol) is obtained. This product is converted into 1-(indolin-1-yl)-2-methyl- isothiourea hydroiodide by heating up for 1 hour with methyl iodide in methanol. The free base is obtained by addition of aqueous sodium hydroxide and is further reacted with a 2N methanolic solution of hydrochloric acid to give l-(indolin-l-yl)-2-methylisothiourea hydrochloride (M.P. 227-229° - from methanol/ether).
-
- The compounds of formula I exhibit pharmacological activity. In particular, the compounds possess vasoconstricting
activity, as indicated by standard tests. For example, this activity may be observed in vivo in rats treated in accordance with the principles of J.S. Gillespie and T.C. Muir, Br.J. Pharmac.Chemother. (1967) 30, 78-87): a pressor effect is elicited following i.v. administration of from about 0.02 to about 50 µg/kg, particularly of from about 0.02 to about 0.5 pg/kg of the compounds. - The compounds are therefore indicated for use as vasoconstricting agents, e.g. for the prophylaxis and treatment of vascular headaches such as migraine, and of orthostatic disorders such as orthostatic hypotension and its symptoms, such as vertigo.
- For this use an indicated daily dose is from about 0.0025 to about 1 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage from containing from about 0.0005 to about 0.5 mg, or in sustained release form.
- The activity of the compound of Example 1 is especially interesting.
- The compounds of formula I may be administered in free form or in pharmaceutically acceptable acid addition salt form. Such forms exhibit the same order of activity as the free form. The present invention also provides a pharmaceutical composition comprising a compound of formula I, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent. Such compositions may be in the form of, for example, a solution or a tablet.
Claims (10)
n is 2, 3 or 4,
which comprises cyclizing a compound of formula II,
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH7915/77 | 1977-06-28 | ||
CH791577 | 1977-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000151A1 true EP0000151A1 (en) | 1979-01-10 |
EP0000151B1 EP0000151B1 (en) | 1981-05-20 |
Family
ID=4332315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100166A Expired EP0000151B1 (en) | 1977-06-28 | 1978-06-15 | 1-substituted aminoindolines, process for their production and pharmaceutical compositions containing them |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0000151B1 (en) |
JP (1) | JPS5412373A (en) |
AU (1) | AU3746878A (en) |
CA (1) | CA1094553A (en) |
DE (1) | DE2860709D1 (en) |
DK (1) | DK275278A (en) |
ES (1) | ES471125A1 (en) |
FI (1) | FI781947A (en) |
IL (1) | IL55005A (en) |
IT (1) | IT7850073A0 (en) |
NZ (1) | NZ187675A (en) |
PT (1) | PT68217A (en) |
ZA (1) | ZA783708B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT7950924A0 (en) * | 1978-12-13 | 1979-11-28 | Sandoz Ag | DERIVATIVES OF 1-AMINOINDOLIN THEIR PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS |
DE3133302A1 (en) * | 1981-08-22 | 1983-03-03 | Beiersdorf Ag, 2000 Hamburg | ISOINDOLIN-2-YL-AMINO-IMIDAZOLINE AND ISOINDOLIN-2-YL-GUANIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
DE3343801A1 (en) * | 1983-12-03 | 1985-06-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW INDOLDER DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH529702A (en) * | 1970-07-06 | 1972-10-31 | Sandoz Ag | Optically active benz(c,d)indole derivs - with vasoconstrictive and cns - smoothing activity |
FR2230363A1 (en) * | 1973-05-25 | 1974-12-20 | Lepetit Spa |
-
1978
- 1978-06-15 EP EP78100166A patent/EP0000151B1/en not_active Expired
- 1978-06-15 DE DE7878100166T patent/DE2860709D1/en not_active Expired
- 1978-06-19 DK DK275278A patent/DK275278A/en unknown
- 1978-06-19 FI FI781947A patent/FI781947A/en not_active Application Discontinuation
- 1978-06-26 AU AU37468/78A patent/AU3746878A/en active Pending
- 1978-06-26 IL IL55005A patent/IL55005A/en unknown
- 1978-06-26 PT PT68217A patent/PT68217A/en unknown
- 1978-06-26 ES ES471125A patent/ES471125A1/en not_active Expired
- 1978-06-26 NZ NZ187675A patent/NZ187675A/en unknown
- 1978-06-26 CA CA306,210A patent/CA1094553A/en not_active Expired
- 1978-06-27 JP JP7708578A patent/JPS5412373A/en active Pending
- 1978-06-28 IT IT7850073A patent/IT7850073A0/en unknown
- 1978-06-28 ZA ZA783708A patent/ZA783708B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH529702A (en) * | 1970-07-06 | 1972-10-31 | Sandoz Ag | Optically active benz(c,d)indole derivs - with vasoconstrictive and cns - smoothing activity |
FR2230363A1 (en) * | 1973-05-25 | 1974-12-20 | Lepetit Spa |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
IL55005A (en) | 1981-12-31 |
IT7850073A0 (en) | 1978-06-28 |
AU3746878A (en) | 1980-01-03 |
IL55005A0 (en) | 1978-08-31 |
ES471125A1 (en) | 1979-09-16 |
JPS5412373A (en) | 1979-01-30 |
PT68217A (en) | 1978-07-01 |
DE2860709D1 (en) | 1981-08-27 |
DK275278A (en) | 1978-12-29 |
FI781947A (en) | 1978-12-29 |
EP0000151B1 (en) | 1981-05-20 |
NZ187675A (en) | 1981-02-11 |
ZA783708B (en) | 1980-02-27 |
CA1094553A (en) | 1981-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100191973B1 (en) | 5-arylindole derivatives | |
KR101221864B1 (en) | Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide, methods for the production thereof, and use thereof as medicaments | |
AU727013B2 (en) | Heterocyclic compound and antitumor agent comprising the same as effective component | |
EP0690843B1 (en) | Formyl- or cyano- substituted indole derivatives having dopaminergic activity | |
KR20040087335A (en) | Nitrogen-Containing Heterocyclic Compound | |
JPH0739387B2 (en) | Novel 1-benzyl-aminoalkyl-pyrrolidinone compound and method for producing the same | |
UA45325C2 (en) | BENZONITRILES AND BENZOFLUORIDES, THE METHOD OF OBTAINING THEM, THE PHARMACEUTICAL COMPOSITION, THE METHOD OF OBTAINING IT, THE METHOD OF CONTROLLING THE DISEASE | |
US4575508A (en) | 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents | |
GB2243832A (en) | 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative | |
EP0599240B1 (en) | Indole-7-carboxamide derivatives as analgesics | |
US3579524A (en) | 2-aminoalkyl derivatives of phthalimidines | |
US4213984A (en) | 11-(Piperazino-acetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and salts thereof | |
EP0000151B1 (en) | 1-substituted aminoindolines, process for their production and pharmaceutical compositions containing them | |
CS226008B2 (en) | Method of preparing piperidinopropyl derivatives | |
US3530140A (en) | Certain pyridyl-hydrazino-2-yl-imidazolines | |
CZ280490A3 (en) | Pyridobenzoindole derivatives, process of their preparation and a pharmaceutical containing thereof | |
NZ201642A (en) | 1-phenylindazol-3-one derivatives and pharmaceutical compositions | |
US3184466A (en) | Beta amino butyrylxnbqlines | |
US3576811A (en) | 1-alkyl-1-(beta-piperidino-ethyl)-1,2,3,4- tetrahydronaphthalen-2-ones | |
US4681881A (en) | 5-alkoxy-pyrido[4,3-d]pyrimidine derivatives | |
IE43727B1 (en) | Dibenzo/b,e//1,4/diazepines | |
US3635962A (en) | 4 - bis-morpholino- and 2 | |
EP0427860A1 (en) | New imidazole derivatives, production thereof, and uses thereof as medicines | |
KR100917041B1 (en) | New compounds of 5-ht7 receptor antagonist | |
US3308133A (en) | Novel alkylene diamine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB LU NL SE Designated state(s): BE CH DE FR GB LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19810615 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19810619 Year of fee payment: 4 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19810630 Ref country code: CH Effective date: 19810630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19810630 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19810731 Year of fee payment: 4 |
|
REF | Corresponds to: |
Ref document number: 2860709 Country of ref document: DE Date of ref document: 19810827 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19820616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19830101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19830201 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19830331 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100166.4 Effective date: 19850612 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |